Introduction {#s1}
============

ME-344 as a synthetic isoflavone analog of phenoxodiol with structural similarities to genestein, is currently in clinical trial in cancer patients ([@B5]; [@B15]). One requirement toward attaining regulatory approval for the drug is to define its mechanism of action. Presently, it is apparent that mitochondria are directly impacted by drug treatment, but more than one molecular target has been identified. Possible interactive promiscuity is exemplified by reports that the drug induced inhibition of respiratory complexes ([@B2]; [@B24]; [@B28]; [@B30]) and translocation of heme oxygenase 1 (HO-1) from rough endoplasmic reticulum to mitochondria ([@B28]). In addition, ME-344 also causes increased mitochondrial reactive oxygen species (ROS) production, Bax-mediated loss of mitochondrial membrane potential (ΔΨ~m~) ([@B2]; [@B59]), and inhibition of mitochondrial permeability transition (MPT) ([@B1]; [@B59]). MPT is mediated through the opening/closing of a supramolecular complex permeability transition pore (PTP) between the inner and outer mitochondrial membranes. The molecular entities of the MPT pore are still debated, although hexokinase, voltage-dependent anion channels (VDACs), adenine nucleotide translocase, and cyclophilin D have been proposed to be components of the pore ([@B61]; [@B7]). Bax, as a member of the Bcl-2 protein family, exists in equilibrium between mitochondria and cytosol ([@B41]) and is also critical in maintaining MPT ([@B54]).

We recently used a click chemistry version of ME-344 and showed that it binds to and inhibits HO-1. Proteomic analyses also indicated that VDAC1 and 2 were binding targets ([@B58])(Zhang, 2019). VDAC, a highly conserved ∼30-kDa protein with three isoforms in humans (VDAC1, 2, and 3), is the most abundant protein in the mitochondrial outer membrane. Respiratory substrates, such as cytosolic ATP, ADP, and Pi entering mitochondria and mitochondrial ATP moving to the cytosol, cross the mitochondrial outer membrane through VDAC ([@B10]). The distribution of VDAC isoforms varies from cell to cell and from cancer cell line to cancer cell line, but, in general, VDAC1 and VDAC2 are the most abundant isoforms. VDAC1, the most studied isoform, has been proposed to play important roles in several physiologic processes, including calcium signaling, regulation of cellular bioenergetics, and ROS control. VDAC2, implicated in the regulation of apoptosis, is also a major contributor of mitochondrial metabolism, whereas the minor isoform VDAC3 only recently has been shown to be a pore-forming channel ([@B14]; [@B29]; [@B27]; [@B32]; [@B39]). Accumulating evidence indicates that VDACs play a role in determining cell survival ([@B40]; [@B22]; [@B19]) or apoptosis ([@B4]; [@B16]; [@B3]; [@B20]; [@B56]). Perhaps related to their interaction with the Bcl-2 family member Bax, VDAC1 and 2 have been implicated in regulation of apoptosis ([@B26]; [@B8]). Silencing of VDAC1 or VDAC2 effectively prevents the association of Bcl-2 protein with mitochondria and inhibits Bax function and apoptosis induced by anticancer drugs ([@B45]; [@B55]; [@B9]; [@B11],[@B12]).

It has been recently proposed that VDAC operates as a switch for global control of mitochondrial metabolism in cancer cells. Moreover, small molecules that cause VDAC opening increase mitochondrial metabolism and generation of ROS and decrease levels of enhanced glycolysis, acting as anti-Warburg compounds ([@bib62])([@bib63])([@bib64])([@bib65])(Maldonado, 2017; DeHart et al., 2018; Maldonado and Fang, 2018; Heslop et al., 2020).

Since our previous click chemistry/proteomics analysis showed that ME-344 binds to VDAC1 and VDAC2, we undertook the present studies, focusing on these two isoforms to determine their relevance in drug-response patterns in lung cancer cell lines that are either intrinsically sensitive or resistant to ME-344.

Materials and Methods {#s2}
=====================

 {#s3}

### Cell Lines. {#s4}

H460 large-cell lung cancer cells were from the National Cancer Institute (Frederick, MD), and H596 adenosquamous lung carcinoma cells were from American Type Culture Collection. Each collection of cells was maintained in RPMI1640 medium (Corning, NY) supplemented with 10% (v/v) FBS (Atlas), 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine. Cell lines were authenticated as described previously ([@B58]).

### Antibodies. {#s5}

The following antibodies were used for immunoblots: Mouse monoclonal anti-ATP5A (ab110273) was from Abcam, Cambridge, MA; Mouse monoclonal anti-cytochrome c was from R&D SYSTEMS, Minneapolis, MN; Mouse monoclonal anti-Bax (B9054) and mouse monoclonal anti-*β*-actin were from Sigma, St. Louis, MO; and IRDye 800CW Goat anti-Mouse IgG, IRDye 800CW Goat anti-Rabbit IgG, IRDye 680RD Goat anti-mouse IgG, and IRDye 680RD Goat anti-Rabbit IgG were all from LI-COR, Lincoln, NE.

### Trypan Blue Assay. {#s6}

To determine the cell viability by vital dye exclusion tests, 20 μl of cell suspension was mixed with 20 μl of 0.4% trypan blue solution (Sigma-Aldrich) for 5 minutes. The number of viable cells was counted using a hemocytometer. Each experiment was carried out a minimum of three independent times. Mean and S.D. were calculated for each subculture.

### ROS Detection. {#s7}

ROS detection was performed as previously described ([@B58]). Cells were treated with 1 mM 2′,7′-dichlorodihydrofluorescein diacetate (CM-H~2~DCFDA; Thermo Fisher Scientific) for 45 minutes, and this was followed by washing two times with PBS. The reduced CM-H~2~DCFDA could be oxidized and converted into fluorescent 2′,7′-dichlorofluorescein by intracellular ROS. The fluorescent signals were detected by flow cytometer (Beckman Coulter). In total, 10,000 cells were analyzed per sample.

### Small Interfering RNA Treatment. {#s8}

Cells grown to 70%--80% confluence were transfected with small interfering (si) RNA (50 nM) targeting VDAC1, VDAC2, and VDAC3 or control nontarget siRNA (Ambion, Austin, TX). Nontarget siRNA was Silencer Select Negative Control \#1 siRNA (Catalog 4390844). siRNAs for VDAC1, VDAC2, and VDAC3 were Silencer Select siRNAs: VDAC1, Catalog 4390824, ID: s14769; VDAC2, Catalog 4392420, ID: s14771; and VDAC3, Catalog 4392420, ID: s230730. siRNAs were reverse transfected using LipofectAMINE RNAiMAX Transfection Reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA).

### RNA Isolation and Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction. {#s9}

RNA isolation and real-time polymerase chain reaction (PCR) were performed as described previously ([@B58]). Total RNA was prepared using the Isolate II RNA Mini Kit (Bioline USA, Inc.), and cDNA was then synthesized with the iScript cDNA Synthesis Kit (Bio-Rad). Subsequently, quantification of gene expression was performed in duplicate using iQ SYBR Green Supermix (Bio-Rad) with detection on a MyiQ Real-Time PCR System (Bio-Rad). The reaction cycles used were 95°C for 5 minutes, 40 cycles at 95°C for 15 seconds, and 58°C for 1 minute, and this was followed by melt curve analysis. Relative gene expression quantification was based on the comparative threshold cycle method (∆∆Ct) with normalization of the raw data to the housekeeping gene (18S ribosomal RNA).

### Loading of Tetramethylrhodamine Methylester and Laser-Scanning Confocal Microscopy. {#s10}

H460 (drug-sensitive) and H596 (drug-resistant) cells plated in MatTek dishes were loaded with 200 nM tetramethylrhodamine methylester (TMRM) for 30 minutes in modified Hank's balanced salt solution containing (in millimolars): 137 NaCl, 0.35 Na~2~HPO~4~, 5.4 KCl, 1 KH~2~PO~4~, 0.81 MgSO~4~, 0.95 CaCl~2~, 5.5 glucose, 25 NaHCO~3~, and HEPES 20, pH 7.4, or complete growth media. After the initial loading, cells were maintained in 50 nM TMRM to maintain the equilibrium of distribution ([@bib66])(Lemasters and Ramshesh, 2007). Cells incubated in modified Hank's balanced salt solution in a humidified 5% CO~2~/air at 37°C were imaged with a Zeiss LSM 880 NLO inverted laser-scanning confocal microscope (Thornwood, NY) with a 63 × 1.4 numerical aperture plan apochromat oil immersion lens. TMRM was excited at 561 nm, and emission signal was detected with a Quasar multichannel spectral detector at 590--610 nm through a one--Airy unit diameter pinhole ([@B27]).

### 5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetra-ethylbenzimidazolylcarbocyanine iodide Staining. {#s11}

Cells were stained with the mitochondrial membrane potential sensitive probe, JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetra-ethylbenzimidazolylcarbocyanine iodide) (Invitrogen), at a final concentration of 2 µM in PBS for 15 minutes at 37°C. After two PBS washes (300*g*, 5 minutes), labeled cells were observed with an Olympus FV10i laser-scanning confocal. The aggregate red form of JC-1 has absorption/emission maxima of 585/590 nm, whereas the green monomeric form is 510/527 nm. Images acquired from confocal microscopy were measured and calculated for mean fluorescence intensities using ImageJ software version 1.41 (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, MD). For flow cytometry, JC-1 aggregates were measured in the fluorescence 2 channel, and JC-1 monomer was measured in the fluorescence 1 channel. Fluorescence-activated cell sorter data were analyzed by CytExpert.

### Apoptosis Assay. {#s12}

Annexin V and PI staining were performed according to the manufacturer's instructions (556547; BD Pharmingen). Cells were washed twice with cold PBS and then resuspended in 1× Binding Buffer at a concentration of 1 × 10^6^ cells/ml. One hundred microliters of the solution (1 × 10^5^ cells) was transferred to a 5-ml culture tube and 5 µl of FITC Annexin V and 5 µl PI were added. Cells were vortexed and incubated for 15 minutes at 25°C in the dark. Four hundred microliters of 1× Binding Buffer was added to each tube and subject to flow cytometry within 1 hour.

### Purification of Mitochondria and Cytosol. {#s13}

Mitochondria and cytosol fractions were isolated as previously described ([@B51]). Purities of cell fractions were determined by immunoblotting against *β*-actin (cytosol marker), ATP5A (mitochondrial marker), and sarco/endoplasmic reticulum (ER) Ca^2+^-ATPase (ER marker).

### Immunoblotting. {#s14}

Immunoblotting was performed as previously described ([@B58]). Total soluble protein was quantitated by bicinchoninic acid protein assay (Pierce). Mitochondria and cytosol fractions were resolved in an SDS-loading buffer \[80 mM Tris-HCl, pH 6.8; 2% SDS; 10% glycerol; 0.02% bromophenol blue; 5 mM Tris(2-carboxyethyl)phosphine\] and heated at 95°C for 5 minutes. Equal amounts (50 μg) of protein were electrophoretically separated by SDS-PAGE (Bio-Rad) and transferred onto low fluorescent polyvinylidene fluoride membranes (Millipore) by the Trans-Blot Turbo Transfer System (Bio-Rad). PVDF or nitrocellulose membranes were incubated in the Odyssey blocking buffer (LI-COR) for 1 hour to reduce nonspecific binding and then probed with appropriate primary antibodies at 4°C overnight. Immunoblots were then developed with infrared fluorescence IRDye secondary antibodies (LI-COR) at a dilution of 1:15,000, imaged with a 2-channel (red and green) infrared fluorescent Odyssey CLx imaging system (LI-COR), and quantified with ImageJ software (FIJI).

### Click Chemistry and Affinity Enrichment Mass Spectrometry. {#s15}

Click chemistry and liquid chromatography tandem mass spectrometry were performed as previously described ([@B58]). However, whereas the previous analysis focused only on drug-enriched proteins of 25--50 kDa, the present study was expanded. All proteins enriched by ME-344 beads (or negative controls) were fractionated into six gel bands before in-gel digestion and analyzed by liquid chromatography tandem mass spectrometry. Quantitative results were extracted and analyzed using MaxQuant and Perseus. Proteins were filtered to retain only those quantified in duplicate ME-344 enrichments, and missing values in the control enrichment were recorded as previously described ([@B58]).

Protein interaction and annotation networks were generated using a web-based tool, NDEx ([@B37], [@B36]; [@B35]). Protein interactions associated with enriched proteins were extracted from multiple protein interaction data bases accessible in NDEx (BIOGRID, String, HumanNet, HIPPIE) and merged and visualized with Cytoscape 3.8.0 ([@B42]; [@B33]). Annotated gene-pathway relationships of VDAC1 and VDAC2 curated in the Comparative Toxicogenomics Database ([@B13]) were accessed through NDEx Integrated Query and visualized with Cytoscape.

### Statistical Analysis. {#s16}

All measurements were collected from three independent experiments. Statistical analysis was performed using GraphPad Prism 6.0 and Microsoft Excel. Significant differences were determined using two-tailed *t* tests. The results are expressed as the mean ± S.D. Significance levels were established at a level of *P* \< 0.05.

Results {#s17}
=======

 {#s18}

### ME-344 Binds Directly to VDAC1 and 2. {#s19}

Using a monopropargylated derivative of ME-344 (M2F) ([Supplemental Fig. 1](http://jpet.aspetjournals.org/lookup/suppl/doi:10.1124/jpet.120.000009/-/DC1)) with azide agarose resin ([@B58]), we identified protein binding via affinity enrichment mass spectrometry. Our previous study focused on a single, differentially stained gel band, whereas the analysis described in this report was designed to discern differentially enriched proteins from full protein profiles. The relative abundance of proteins enriched by M2F-conjugated beads was compared with control resin measured by label-free proteomics ([Supplemental Table 1](http://jpet.aspetjournals.org/lookup/suppl/doi:10.1124/jpet.120.000009/-/DC1)). Twelve proteins were enriched by M2F beads, as determined by a \>2.5 log~2~ fold change compared with control beads. These included VDAC1 and 2, enriched by 3.55- and 3.25-log~2~--fold, respectively ([Fig. 1A](#F1){ref-type="fig"}). Enriched proteins were queried for known interactions, and the resulting protein interaction networks were uploaded and merged with the drug-protein interaction network in Cytoscape. This analysis revealed VDAC1 and 2 were central to the network, interacting with five of the other enriched proteins, indicating direct binding of the drug to VDAC and enrichment of VDAC-binding proteins ([Fig. 1B](#F1){ref-type="fig"}). Functional annotations associated with VDAC1 and 2 are shown in [Fig. 1C](#F1){ref-type="fig"}.

![VDAC1 and 2 were identified as ME-344 targets in H460 cells by using click chemistry and mass spectrometry. Affinity-enriched and gel-fractionated proteins between 10 and 250 kDa were analyzed by LC/MS-MS and quantified by label-free proteomics. (A) Proteins with a log~2~ fold change in intensity \>2.5 were considered enriched with M2F, as compared with control beads. (B) Twelve proteins enriched with M2F were queried for known protein interactions revealing VDAC1 and 2 interactions with five of the other enriched proteins. This network of interactions was visualized with Cytoscape. (C) Functional annotations for VDAC1 and 2 extracted from the Reactome and Kyoto Encyclopedia of Genes and Genomes data bases. cGMP-PKG, Cyclic guanosine monophosphate protein kinase G;GOLT1B, Vesicle transport protein GOT1B;MTCH2, Mitochondrial carrier homolog 2;MT-CO2, Cytochrome c oxidase subunit 2;NOD, Nucleotide-binding and oligomerization domain;PHB2, Prohibitin-2;TOMM22, Mitochondrial import receptor subunit TOM22 homolog.](jpet.120.000009f1){#F1}

### VDAC Expression, ROS Production, and Drug Response. {#s20}

As assessed by qPCR, all three VDAC isoforms were expressed in both H460 and H596 cells. Proportionally, VDAC2 (48% and 60%) was the most abundant, followed by VDAC1 (30% and 27%) and VDAC3 (22% and 13%, respectively; [Fig. 2A](#F2){ref-type="fig"}). We previously established that H460 cells are sensitive and H596 cells are intrinsically resistant to ME-344 and found no significant difference of basal protein levels of VDAC1 and VDAC2 in H460 and H596 cells. However, when challenged with ME-344, fold changes of VDAC1 and VDAC2 were both more pronounced in H460 cells than H596 cells. Interestingly, Medical Research Council cell strain 5 cells, normal lung fibroblast cells, were more closely aligned to the resistant cells than to the sensitive cells in the expression of VDAC1 and VDAC2 after ME-344 treatment ([Supplemental Fig. 2](http://jpet.aspetjournals.org/lookup/suppl/doi:10.1124/jpet.120.000009/-/DC1)) ([@B58]). Isoform-specific siRNAs selectively inhibited expression of VDAC1, 2, and 3, respectively. siRNA treatment decreased both mRNA and protein expression by approximately 90% for each isoform without causing compensatory increases on expression of the other isoforms ([Fig. 2, B and C](#F2){ref-type="fig"}). Response to ME-344 (trypan blue assay) and ROS production were determined after individual knockdown of each isoform in comparison with non--target-treated cells. The cell viabilities were shown in [Fig. 2, D and E](#F2){ref-type="fig"} and [Supplemental Table 2](http://jpet.aspetjournals.org/lookup/suppl/doi:10.1124/jpet.120.000009/-/DC1). The IC~50~s for ME-344 in siVDAC1 and siVDAC2 knockdown H460 cells increased by 46.7% and 37.4%, respectively, compared with nontarget siRNAs. There were no significant changes of IC~50~s in H596 cells. Knockdown of VDAC1 or 2 slightly decreased basal ROS levels, whereas VDAC 3 knockdown increased basal ROS levels in H460 cells ([Fig. 2, F and G](#F2){ref-type="fig"}). ROS production of H596 cells was unaffected ([Fig. 2, H and I](#F2){ref-type="fig"}). Since ROS can induce mitochondrial permeability transition pore opening, we measured how ROS levels were influenced by VDAC knockdown. Reduced VDAC1 or 2 levels resulted in decreased ROS generation, whereas knockdown of VDAC3 increased ROS production induced by ME-344 compared with nontarget siRNA ([Fig. 3](#F3){ref-type="fig"}).

![Manipulation of VDAC1/2 expression impacts drug response. (A) Expression of VDAC isoforms VDAC1, VDAC2, and VDAC3 in H460 and H596 cell lines were determined by qPCR. (B and C) After transfection, mRNA and protein expression of the corresponding VDAC isoforms were assessed by qPCR and Western blot. (D and E) After transfection, H460 and H596 cell lines were treated with ME-344 (0--100 µM) for 24 hours, and viabilities were determined by trypan blue assay in which % viability was calculated relative to nontarget control. (F and H) Basal intracellular ROS levels determined with CM-H~2~DCFDA by flow cytometry. (G and I) Statistical analyses of cell ROS levels. Data are derived from three independent experiments and presented as mean ± S.D. in the scatter plots. \**P* \< 0.05; vs. the untreated control by Student's *t* test.](jpet.120.000009f2){#F2}

![Manipulation of VDAC1/2 expression impacts ROS production. (A--D) Cells were treated with their IC~50~s of ME-344 for 24 hours, and intracellular ROS levels were determined with CM-H~2~DCFDA by flow cytometry. (E--H) Statistical analyses of cell ROS levels. Data are derived from three independent experiments and presented as means ± S.D. in the scatter plots. \**P* \< 0.05; \*\**P* \< 0.01 vs. the untreated control by Student's *t* test. Ctrl, control.](jpet.120.000009f3){#F3}

Knockdown of VDAC1 or 2 decreased apoptosis induced by ME-344 in H460 cells. The respective contributions of early- (Annexin V-FITC positive, PI negative) and late-stage apoptosis (both Annexin V-FITC and PI positive) were measured in H460 cells after ME-344. The results showed that apoptosis rates increased in a dose-dependent manner in comparison with untreated cells. H596 cells were unaffected by similar drug concentrations ([Fig. 4](#F4){ref-type="fig"}). Knockdown of either VDAC1 or 2 did, however, decrease the levels of apoptosis induced by ME-344 compared with nontarget siRNA ([Fig. 5](#F5){ref-type="fig"}).

![Impact of ME-344 on apoptosis. (A and B) ME-344--treated cells were cultured for 24 hours prior to staining with Annexin V and PI. (C and D) Statistical analyses of cell apoptosis. Live: Annexin V and PI double negative cells. Apoptosis: Annexin V positive, PI positive, or negative cells. Data are derived from three independent experiments and presented as mean ± S.D. in the scatter plots. \**P* \< 0.05; \*\*\**P* \< 0.001 vs. the untreated control by Student's *t* test.PI, Propidium iodide.](jpet.120.000009f4){#F4}

![Manipulation of VDAC1/2 expression impacts apoptosis. (A--H) ME-344--treated (at their IC~50~s: 10.05 ± 0.28, 14.74 ± 0.32, 13.81 ± 0.23, 9.38 ± 0.29 μM, respectively) VDAC knockdown cells were cultured for 24 hours prior to staining with Annexin V and PI. (I--L) Statistical analyses of cell apoptosis. Live: Annexin V and PI double negative cells. Apoptosis: Annexin V positive, PI positive, or negative cells. Data are derived from three independent experiments and presented as mean ± S.D. in the scatter plots. \*\**P* \< 0.01 vs. the untreated control by Student's *t* test. KD, Knock down; PI, Propidium iodide.](jpet.120.000009f5){#F5}

### ME-344 Effects on Mitochondrial Membrane Potential. {#s21}

Loss of ΔΨ~m~ is an indicator of mitochondrial dysfunction that, in some cases, triggers the release of cytochrome c from mitochondria to the cytoplasm and activates the apoptotic caspase cascade. Previously, we showed that ME-344--induced apoptosis by activation of caspase-3 led to the cleavage of poly(ADP-ribose) polymerase ([@B57]). In this regard, ME-344 treatment decreased ΔΨ~m~ in a dose-dependent manner in H460 cells, as shown by confocal imaging of JC-1 fluorescence ([Fig. 6, A and B](#F6){ref-type="fig"}) and flow cytometry ([Fig. 6, C and D](#F6){ref-type="fig"}). These effects were not apparent for the resistant H596 cells ([Fig. 6, E--H](#F6){ref-type="fig"}).

![Impact of ME-344 on mitochondrial membrane potentials. After ME-344, cells were cultured for 24 hours prior to: (A and E) Red images indicate JC-1 aggregate fluorescence in healthy mitochondria, whereas green represents cytosolic JC-1 monomers. Merged images indicate colocalization of JC-1 aggregates and monomers. Scale bar, 10 µm. Images are representative of three independent experiments. (B and F) Mean fluorescence intensity (MFI) fold change quantification of JC-1 green/red ratio in control and ME-344 treatment groups. (C and G) Mitochondrial membrane potential (MMP) loss assay by flow cytometry. The right lower region of dot plots for JC-1 stain represents JC-1 positive cells (green color). The right upper region represents JC-1 negative cells (red color). (D and H) The percentage of JC-1 positive cell lines in control and ME-344 treatment groups. Data are derived from three independent experiments and presented as mean ± S.D. in the scatter plots. \*\**P* \< 0.01; \*\*\**P* \< 0.001 vs. the untreated control by Student's *t* test.](jpet.120.000009f6){#F6}

To assess the time at which ΔΨ~m~ began to change in H460 and H596 cells, we loaded cells with the potential-indicating fluorophore TMRM and subsequently imaged with confocal microscopy. Vehicle- or ME-344--treated cells in the same fields were followed for 3 hours. ME-344 induced significant depolarization of ΔΨ~m~ within 15 minutes in H460 cells (approximately 40%) and by more than 60% at the end of the 3-hour treatment ([Fig. 7, A and B](#F7){ref-type="fig"}). No significant depolarization was induced by ME-344 in H596 cells ([Fig. 7, C and D](#F7){ref-type="fig"}). These data were confirmed using flow cytometry ([Fig. 7, E--H](#F7){ref-type="fig"}). To assess the impact of silencing VDAC on ΔΨ~m~, both H460 and H596 cells were transfected with either nontarget or VDAC1, 2, and 3 siRNAs and subsequently loaded with TMRM and imaged by confocal microscopy. In nontarget siRNA H460 cells, mitochondria expressed strong labeling with TMRM ([Fig. 8A](#F8){ref-type="fig"}). Knockdown of VDAC isoforms 1, 2, and 3 decreased mitochondrial TMRM fluorescence by 19%, 18%, and 26%, respectively. The most significant decrease of ΔΨ~m~ occurred after knockdown of VDAC3, the least abundant isoform ([Fig. 8B](#F8){ref-type="fig"}). ME-344 reduced the TMRM fluorescence in mitochondria, which was indicated by reduction in ΔΨ~m~ in H460 cells ([Fig. 8, A and C](#F8){ref-type="fig"}). This drug-induced dissipation of ΔΨm was diminished by knockdown of either VDAC1 or 2 in H460 cells ([Fig. 8, A and C](#F8){ref-type="fig"}).

![ME-344 decreases mitochondrial membrane potential in drug-sensitive cells. (A and C) Representative images of TMRM staining on H460 (sensitive) and H596 (resistant) cells. Cells were treated with either DMSO or ME-344, and the same fields followed for 3 hours. (B and D) Quantification of mean intensity of TMRM fluorescence. Data normalized to baseline of DMSO (baseline = 1). (E and G) ME-344--treated cells were cultured for different times prior to TMRM staining, and mitochondrial membrane potential (MMP) was measured by flow cytometry. Representative results of TMRM staining. (F and H) Statistical analysis of mitochondrial membrane potential. Data are derived from three independent experiments and presented as mean ± S.D. in the scatter plots. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 vs. the untreated control by Student's *t* test. a.u., Arbitrary units.](jpet.120.000009f7){#F7}

![VDAC knockdown decreases mitochondrial membrane potential, and VDAC1 and 2 knockdown induces recovery of mitochondrial membrane potential in sensitive cell line H460. (A) Representative images of TMRM staining on post-transfection H460 cells. Cells were treated with ME-344, and the same fields were followed for 1 hour after treatment. (B) Mean basal TMRM fluorescence after knockdown was plotted in comparison with transfection with nontarget siRNA. (C) Quantification is mean intensity of TMRM fluorescence. Data are normalized to baseline (baseline = 1). Data are derived from three independent experiments and presented as mean ± S.D. in the scatter plots. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 vs. the baseline control by Student's *t* test. a.u., Arbitrary units.](jpet.120.000009f8){#F8}

### VDAC1 and 2 Are Required for Bax to Mediate ME-344--Induced Apoptosis in H460 Cells. {#s22}

Bax translocation from cytosol to mitochondria induces cytochrome c release, followed by caspase activation of apoptosis ([@B46]; [@B18]; [@B50]). To determine whether VDACs influence this process, Bax and cytochrome c levels were determined in mitochondria and cytosol in both H460 and H596 cells. ME-344 treatments of H460 with VDAC1 or 2 knockdown decreased both Bax translocation from cytosol to mitochondria and release of cytochrome c. These effects were not found in either VDAC3 or nontarget knockdowns ([Fig. 9, A and B](#F9){ref-type="fig"}). Bax translocation and cytochrome c release were not affected in transfected H596 cells ([Fig. 9, C and D](#F9){ref-type="fig"}). Taken together, these results showed that VDAC1 and 2, but not 3, influenced ME-344--mediated Bax translocation --mediated apoptosis in H460 cells.

![VDAC1 and 2 knockdown prevented ME-344--induced Bax translocation and cytochrome c release in sensitive cell line H460. (A and C) H460 and H596 cells transfected with nontarget or siVDAC1, 2, 3 were all treated with ME-344 and mitochondria and cytosol-isolated. Proteins were separated by SDS-PAGE and evaluated by immunoblots. (B and D) Protein expression after ME-344 was quantified by ImageJ software in either mitochondrial or cytosol fractions relative to nontarget control cells. *β*-Actin as cytosol marker; ATP5A as mitochondria marker; sarco/ER Ca^2+^-ATPase (SERCA) as ER marker. Data are derived from three independent experiments and presented as mean ± S.D. in the scatter plots. \*\**P* \< 0.01; \*\*\**P* \< 0.001 vs. each control group by Student's *t* test. Cyt c, cytochrome c; Cyto, cytosol; Mito, mitochondria.](jpet.120.000009f9){#F9}

Discussion {#s23}
==========

ME-344 has progressed into Phase I/II clinical trials ([@B5]; [@B38]). An overview of preclinical studies indicates that the drug exerts its cytotoxic effects by targeting mitochondria in a number of different cancer types, including lung cancers ([@B59]). The observation that ME-344 can inhibit respiratory complexes with subsequent dysregulation of cellular ROS levels provided impetus for us to consider HO-1 as a potential drug target ([@B2]; [@B24]; [@B28]; [@B30]). We used click chemistry approaches to confirm that HO-1 is a direct target for ME-344 binding and found that it time-dependently inhibited activity of HO-1, bound to and altered HO-1 protein structure, and induced HO-1 translocation from ER to mitochondria. Its inhibition disrupted redox homeostasis leading to mitochodrial-mediated apoptosis ([@B58]). Our proteomic analysis of the click chemistry results also identified other mitochondrial proteins that were plausibly affected by ME-344 treatments. Among these, VDAC1 and VDAC2 were implicated ([@B58]). In light of the role of VDACs in response to oxidative stress ([@B31]), this observation provided a platform for the present study, which was designed to interrogate whether drug effects on these mitochondrial membrane proteins were associated with drug cytotoxicity.

The present results showed that VDAC1 and 2 were enriched by 3.55- and 3.25-log~2~ fold-transformed intensities of drug binding when compared with their respective controls ([Fig. 1](#F1){ref-type="fig"}). By using lung cancer cells that were either either intrinsically sensitive (H460) or resistant (H596) to the drug and employing siRNA to deplete each individual VDAC isoform, we were able to consider their relevance to drug effects. Our results indicated that genetic manipulation of either VDAC1 or 2 expression did influence drug sensitivity, intracellular ROS levels, and induction of apoptosis. Knockdown of either VDAC1 or 2 reduced intracellular ROS levels and made H460 cells less susceptible to ME-344 cytotoxicity. These observations are consistent with other reports showing that VDAC1 silencing lowered both ROS and cell death induced by either selenite ([@B47]) or cisplatin ([@B45]). Contextually, ROSs are known to initiate mitochondrial permeability transition pore (mPTP) opening in mammalian cells ([@B60]). As one of the major putative components of mPTP, VDACs are localized in the outer mitochondrial membrane and are critical components to the formation of this pore ([@B49]). Under physiologic conditions, VDACs facilitate metabolite exchange between mitochondria and cytosol, increase conductance linked to mPTP opening, and dissipate ΔΨ~m~ and eventual cytochrome c release, which are characteristics of the early stages of ME-344 toxicity leading to cell death ([@B43]; [@B48]). Our data show that ME-344 induced loss of ΔΨ~m~ in both nontarget and siVDAC3 H460 cells, but no ΔΨ~m~ changes were detected in siVDAC1- or siVDAC2-treated H460 cells. VDAC1 and 2 knockdown not only prevented the decrease in ΔΨ~m~ after ME-344 but also prevented Bax translocation and cytochrome c release. Bax, as a proapoptotic member of the Bcl-2 family of proteins, is a critical contributor to mitochondrial-mediated apoptosis pathways. Under nonstress conditions, Bax locates predominantly in the cytosol, but various exogenous stresses can cause its translocation to mitochondria as a prelude to apoptosis ([@B21]; [@B23]; [@B50]). Depletion of VDAC1 and 2 prevented both ME-344--induced Bax translocation from cytosol to mitochondria and cytochrome c release from mitochondria to cytosol. These results indicate that in H460 cells the apoptosis caused by ME-344 is contingent upon VDAC1 and 2, and disabling them can contribute to enhanced ROS, thus contributing to the cytoxic properties of ME-344.

There are other drugs that bind to VDAC2 and VDAC3. Erastin causes oxidative stress and mitochondrial dysfunction ([@B53]) through iron accumulation, ROS production resulting in ferroptosis ([@B17]), which is reversible by iron chelation or antioxidants ([@B52]). Since HO-1 initiates catabolism of heme and increases cellular iron levels ([@B44]), ME-344 binding to both HO-1 and VDACs may imply that it shares some properties with erastin. Interactions between VDAC and mitoNEET, an integral outer mitochondrial iron sulfur cluster protein that can regulate VDAC transport in cancer cells, can be disrupted by agents (e.g., pioglitazone) that target VDAC and is redox-dependent ([@B34]; [@B25]). ME-344 appears to have promiscuous affinity for a number of mitochondrial proteins, inducing apoptosis by disrupting mitochondrial homeostasis and promoting ROS production, loss of ΔΨ~m~, Bax translocation, and cytochrome c release. We would argue that these outcomes are downstream of drug binding to VDACs and HO-1 (Zhang, 2019), each of which disrupt the cell's capacity to maintain redox homeostasis. In this instance, knockdown of VDACs diminished the effects that ME-344 triggered in H460 cells, indicating that cellular expression levels of VDAC1 and VDAC2 are essential regulators of apoptosis induction by ME-344 and perhaps some of the other VDAC1-targeting agents discussed elsewhere ([@B6]). This component of the drug's mechanism will be of consequence in the design of combinatorial therapeutic strategies in managing, for example, lung cancer.
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